Equities analysts expect Biogen Inc (NASDAQ:BIIB) to report sales of $3.14 billion for the current quarter, Zacks Investment Research reports. Twenty Eight analysts have made estimates for Biogen’s earnings. The lowest sales estimate is $2.99 billion and the highest is $3.33 billion. Biogen posted sales of $2.81 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 11.7%. The firm is expected to report its next quarterly earnings results on Tuesday, April 24th.
According to Zacks, analysts expect that Biogen will report full year sales of $3.14 billion for the current year, with estimates ranging from $12.76 billion to $13.94 billion. For the next financial year, analysts forecast that the company will post sales of $13.24 billion per share, with estimates ranging from $9.54 billion to $14.98 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Biogen.
Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $5.44 by ($0.18). Biogen had a return on equity of 38.32% and a net margin of 20.69%. The business had revenue of $3.31 billion during the quarter, compared to analysts’ expectations of $3.08 billion. During the same quarter in the prior year, the firm earned $5.04 EPS. The firm’s revenue for the quarter was up 15.1% compared to the same quarter last year.
Biogen (NASDAQ BIIB) traded down $6.20 during mid-day trading on Wednesday, hitting $279.90. The stock had a trading volume of 2,329,746 shares, compared to its average volume of 1,800,000. Biogen has a 52-week low of $244.28 and a 52-week high of $370.57. The company has a quick ratio of 2.07, a current ratio of 2.34 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $59,220.00, a PE ratio of 16.03, a P/E/G ratio of 1.57 and a beta of 0.91.
In other Biogen news, Director Robert W. Pangia sold 5,832 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $329.65, for a total transaction of $1,922,518.80. Following the completion of the sale, the director now owns 23,539 shares of the company’s stock, valued at $7,759,631.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michel Vounatsos purchased 780 shares of the business’s stock in a transaction on Friday, December 29th. The shares were bought at an average cost of $320.55 per share, with a total value of $250,029.00. Following the acquisition, the chief executive officer now directly owns 4,879 shares of the company’s stock, valued at approximately $1,563,963.45. The disclosure for this purchase can be found here. Insiders have sold 8,128 shares of company stock valued at $2,601,512 in the last three months. 0.25% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in BIIB. Captrust Financial Advisors bought a new position in shares of Biogen in the fourth quarter worth about $113,000. Prentiss Smith & Co. Inc. bought a new position in shares of Biogen in the fourth quarter worth about $123,000. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Biogen by 77.0% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 400 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 174 shares during the period. Horan Capital Advisors LLC. bought a new position in shares of Biogen in the third quarter worth about $128,000. Finally, Massey Quick Simon & CO. LLC boosted its stake in shares of Biogen by 84.8% in the third quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 195 shares during the period. 88.96% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Biogen Inc (BIIB) Expected to Post Quarterly Sales of $3.14 Billion” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3258238/biogen-inc-biib-expected-to-post-quarterly-sales-of-3-14-billion.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.